RxDoctor Payments Data

Philip Shumsky, MD

Pain Medicine · Indianapolis, INNPI 1609258763

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Saluda Medical Americas, Inc. accounts for 74.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $14,132 and has fallen 88.1% since, to $1,687 in 2024.

$26,703in general payments, 2019–2025

Across 159 payments — averaging $167.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$20K
  • Abbott$3K
  • Vertos Medical, Inc.$1K
  • Nevro Corp.$579
  • SPR Therapeutics, Inc$451
  • Painteq LLC$219
  • plus $719 from 9 others
$564in research payments, 2019–2025

Across 5 payments — averaging $112.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$564

What the payments were for

  • Consulting fees$15,37558%
  • Travel & lodging$5,23420%
  • Food & beverage$6,09423%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,703 in reported general payments places this provider in the 85th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$425,650
Medicare patients
642
Services billed
5,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine51$14,776
BelbucaBuprenorphine Hcl16$10,198
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen361$6,994
Pregabalin190$6,859
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$6,234
Celecoxib89$5,434
Gabapentin309$4,621
Lidocaine28$2,443
Tizanidine Hcl93$2,192
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen98$1,971
Oxycodone Hcl104$1,813
Cyclobenzaprine Hcl122$1,190
Methocarbamol51$1,084
Naloxone Hcl18$908
Buprenorphine Hcl39$773

Paid to pharmacies, not to this prescriber.

Other pain medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →